Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - Apr 2, 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)

Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. By: Wellington Management Company LLP, as Investment Adviser /s/ Peter McIsaac, Title: Authorized Person
Stock symbol
BOLD
Transactions as of
Apr 2, 2024
Transactions value $
$0
Form type
4
Date filed
4/2/2024, 08:42 PM
Previous filing
Mar 27, 2024
Next filing
Jul 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BOLD Common Stock Conversion of derivative security +190K 190K Apr 2, 2024 Direct F1
transaction BOLD Common Stock Conversion of derivative security +366K +192.86% 556K Apr 2, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BOLD Series B Preferred Stock Conversion of derivative security $0 -3.7M -100% $0.00* 0 Apr 2, 2024 Common Stock 190K Direct F1
transaction BOLD Series C Preferred Stock Conversion of derivative security $0 -7.14M -100% $0.00* 0 Apr 2, 2024 Common Stock 366K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date.
F2 On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date.